Humana Inc. (NYSE:HUM - Free Report) - Equities research analysts at Zacks Research reduced their Q4 2024 earnings per share (EPS) estimates for Humana in a report issued on Wednesday, November 13th. Zacks Research analyst D. Chatterjee now forecasts that the insurance provider will earn ($2.31) per share for the quarter, down from their previous forecast of ($1.64). The consensus estimate for Humana's current full-year earnings is $15.86 per share. Zacks Research also issued estimates for Humana's Q3 2025 earnings at $3.72 EPS, Q4 2025 earnings at $0.30 EPS, FY2025 earnings at $16.65 EPS, Q1 2026 earnings at $6.27 EPS, Q2 2026 earnings at $5.51 EPS, Q3 2026 earnings at $2.90 EPS and FY2026 earnings at $14.96 EPS.
A number of other brokerages have also recently weighed in on HUM. UBS Group reduced their price target on Humana from $380.00 to $250.00 and set a "neutral" rating for the company in a research report on Friday, October 4th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $395.00 price objective on shares of Humana in a research note on Tuesday, October 1st. Bank of America upgraded Humana from an "underperform" rating to a "neutral" rating and upped their price objective for the company from $247.00 to $308.00 in a research note on Wednesday, November 6th. Leerink Partners downgraded Humana from an "outperform" rating to a "market perform" rating and reduced their target price for the stock from $400.00 to $250.00 in a report on Wednesday, October 2nd. Finally, Oppenheimer reduced their target price on Humana from $400.00 to $280.00 and set an "outperform" rating on the stock in a report on Thursday, October 3rd. Twenty equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $315.86.
View Our Latest Stock Analysis on Humana
Humana Price Performance
Shares of NYSE HUM traded down $1.54 during mid-day trading on Monday, reaching $274.13. The company had a trading volume of 1,231,836 shares, compared to its average volume of 1,872,125. The stock has a market cap of $33.01 billion, a PE ratio of 24.42, a P/E/G ratio of 2.17 and a beta of 0.52. The company has a 50-day moving average price of $281.36 and a two-hundred day moving average price of $331.94. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. Humana has a 1-year low of $213.31 and a 1-year high of $527.18.
Humana (NYSE:HUM - Get Free Report) last released its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, topping analysts' consensus estimates of $3.48 by $0.68. The company had revenue of $29.30 billion for the quarter, compared to the consensus estimate of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in HUM. Creative Financial Designs Inc. ADV increased its holdings in shares of Humana by 244.0% during the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider's stock worth $27,000 after purchasing an additional 61 shares during the period. CarsonAllaria Wealth Management Ltd. increased its stake in Humana by 111.4% in the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider's stock valued at $28,000 after acquiring an additional 39 shares during the last quarter. Atwood & Palmer Inc. bought a new position in Humana in the third quarter valued at approximately $29,000. Ashton Thomas Securities LLC bought a new position in Humana in the third quarter valued at approximately $31,000. Finally, Your Advocates Ltd. LLP increased its stake in Humana by 81.8% in the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider's stock valued at $32,000 after acquiring an additional 45 shares during the last quarter. 92.38% of the stock is owned by institutional investors.
Humana Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be given a dividend of $0.885 per share. The ex-dividend date is Tuesday, December 31st. This represents a $3.54 annualized dividend and a yield of 1.29%. Humana's dividend payout ratio (DPR) is presently 31.36%.
About Humana
(
Get Free Report)
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
See Also
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
